Rahul Dhanda is SVP of Corporate Development at T2 Biosystems, Inc. (TTOO). They have made 4 open-market trades across 1 company since 2016, most recently 2017-06-06.
CIK 0001667658
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $4K since 2017, against 3 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| TTOO | 5,667 | $759 |
Shares reported on the most recent Form 4, priced at the 2017-06-08 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TTOO | BUY | 2017-06-06 | 2017-06-08 | $3.50 | $4K | +8.3% | -10.5% | +39.1% |
| TTOO | SELL · 10b5-1 | 2016-06-30 | 2016-07-05 | $8.16 | $29K | -35.3% | -14.2% | -8.3% |
| TTOO | SELL | 2016-03-16 | 2016-03-18 | $8.01 | $61K | +15.6% | +16.9% | +0.0% |
| TTOO | SELL | 2016-03-15 | 2016-03-17 | $8.29 | $114K | +5.3% | +16.5% | +0.7% |
| TTOO | SELL | 2016-03-14 | 2016-03-16 | $8.82 | $24K | +9.0% | +18.6% | +0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.